 |
 |
|
|
RESÚMENES SEPTIEMBRE 2005 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
D2
dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor
symptoms in previously drug-free schizophrenic patients
Regenthal R, Kunstler U,
Hesse S, Sabri O, Preiss R
Int J Clin Pharmacol Ther. 2005 Aug;43(8):370-8
Patterns and predictors of substance use disorders and daily tobacco use
in first-episode psychosis
Darryl Wade, Susy Harrigan, Jane Edwards, Philip M.
Burgess, Greg Whelan, Patrick D. McGorry
Australian and New Zealand Journal of Psychiatry.
Volume 39 Issue 10 Page 892 - October 2005
Laterality phenotypes in patients with schizophrenia, their siblings and controls: associations with clinical and cognitive variables
Milan Dragovic, Geoff Hammond, Johanna C. Badcock, PhD and Assen
Jablensky
The British Journal of Psychiatry (2005) 187: 221-228
Wolfgang Gaebel, Stefan Weinmann, Norman Sartorius, Wolfgang Rutz, John
S. McIntyre
The British Journal of Psychiatry (2005) 187: 248-255
Frank Pillmann, and Andreas Marneros
The British Journal of Psychiatry (2005) 187: 286-287
Relation of Plasma Glycine, Serine, and Homocysteine Levels to Schizophrenia Symptoms and Medication Type
Guy Neeman, Monica Blanaru, Boaz Bloch, Ilana Kremer, Marina Ermilov,
Daniel C. Javitt, and Uriel Heresco-Levy
Am J Psychiatry 162:1738-1740, September 2005
Double-Blind, Placebo-Controlled Investigation of Amantadine for Weight Loss in Subjects Who Gained Weight With Olanzapine
Karen A. Graham, Hongbin Gu, Jeffrey A. Lieberman, Joyce B. Harp, Diana
O. Perkins
Am J Psychiatry 162:1744-1746, September 2005
Effects of Antipsychotic Treatment on Emotion Perception Deficits in First-Episode Schizophrenia
Ellen S. Herbener, S. Kristian Hill, Robert W. Marvin, John A. Sweeney
Am
J Psychiatry 162:1746-1748, September 2005
América Latina: respuesta a los antipsicóticos
Sheila Assunção et
al.
Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable
E. Parellada, R. Andrezina, V. Milanova, P. Glue, M. Masiak, M. St.
John Turner, R. Medori, W. Gaebel
Journal of
Psychopharmacology, Vol. 19, No. 5 suppl, 5-14 (2005)
W. Kissling, S. Heres, K. Lloyd, E. Sacchetti, P. Bouhours, R. Medori,
P. M. Llorca
Journal of Psychopharmacology, Vol. 19, No. 5 suppl,
15-21 (2005)
A. Mohl, K. Westlye, S. Opjordsmoen, A. Lex, A. Schreiner, M. Benoit,
P. Bräunig, R. Medori
Journal of Psychopharmacology, Vol. 19, No. 5 suppl,
22-31 (2005)
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine
M. Gastpar, M. Masiak, M. A. Latif, S. Frazzingaro, R. Medori, E. -R.
Lombertie
Journal of Psychopharmacology, Vol. 19, No. 5 suppl,
32-38 (2005)
Control
Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Scott
W. Woods, Ralitza V. Gueorguieva, C. Bruce Baker, Robert W. Makuch
Arch Gen Psychiatry. 2005;62:961-970
Association Between Duration of Untreated Psychosis and Outcome
in Cohorts of First-Episode Patients. A Systematic
Review
Max
Marshall, Shon Lewis, Austin Lockwood, Richard Drake, Peter Jones, Tim Croudace
Arch Gen Psychiatry. 2005;62:975-983
Comparative and Interactive Human Psychopharmacologic Effects
of Ketamine and Amphetamine. Implications for Glutamatergic and
Dopaminergic Model Psychoses and Cognitive Function
John
H. Krystal, Edward B. Perry, Jr, Ralitza Gueorguieva, Aysenil Belger, Steven H.
Madonick, Anissa Abi-Dargham, Thomas B. Cooper, Lisa MacDougall, Walid
Abi-Saab, D. Cyril D’Souza
Arch Gen Psychiatry. 2005;62:985-994
Treatment
response to olanzapine and haloperidol and its association with dopamine D
receptor occupancy in first-episode psychosis
Zipursky RB, Christensen
BK, Daskalakis Z, Epstein I, Roy P, Furimsky I, Sanger T, Kapur S
Can J Psychiatry. 2005 Jul;50(8):462-9
Differential
contributions of prefrontal and temporolimbic pathology to mechanisms of
psychosis
Suzuki M, Zhou SY, Takahashi T, Hagino H, Kawasaki Y, Niu L, Matsui M, Seto H,
Kurachi M
Brain. 2005 Sep;128(Pt 9):2109-22. Epub 2005 Jun 1
Functional
disconnectivity in subjects at high genetic risk of schizophrenia
Whalley HC, Simonotto E,
Marshall I, Owens DG, Goddard NH, Johnstone EC, Lawrie SM
Brain. 2005 Sep;128(Pt 9):2097-108. Epub 2005 Jun 1
Reduced platelet
vesicular monoamine transporter density in smoking schizophrenia patients
Karin Schwartz,
Iulian Iancu, Rafael Stryjer, Joseph Chelben, Moshe Kotler, Abraham Weizman and
Moshe Rehavi
European Neuropsychopharmacology. Volume 15, Issue 5,
October 2005, Pages 557-561
Olanzapine versus
risperidone in the treatment of post-psychotic depression in schizophrenic
patients
Sonia Dollfus,
Véronique Olivier, Benoît Chabot, Cécile Déal and Elena Perrin
Schizophrenia
Research. Volume 78, Issues 2-3, 15 October 2005, Pages 157-159
Quality of life
during treatment with haloperidol or olanzapine in the year following a first
psychotic episode
Stephen M.
Strakowski, Jacqueline L. Johnson, Melissa P. DelBello, Robert M. Hamer, Alan
I. Green, Mauricio Tohen, Jeffrey A. Lieberman, Ira Glick, Jayendra K. Patel
and HGDH Research Group
Schizophrenia
Research. Volume 78, Issues 2-3, 15 October 2005, Pages 161-169
Obsessive–Compulsive Symptoms and Positive, Negative, and Depressive Symptoms in Patients With Recent-Onset Schizophrenic Disorders
Can J Psychiatry 2005;50:519–524
Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 1: Pathophysiology and Mechanisms of Induction
Can J Psychiatry 2005; 50:541–547
A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness
Lone Petersen,
Pia Jeppesen, Anne Thorup, Maj-Britt Abel, Johan Øhlenschlæger, Torben Østergaard Christensen, Gertrud Krarup, Per Jørgensen, Merete Nordentoft
BMJ 2005;331:602 (17 September)
Patient outcomes
in schizophrenia I: correlates with sociodemographic variables,
psychopathology, and side effects
Alex Hofer, Susanne
Baumgartner, Monika Edlinger, Martina Hummer, Georg Kemmler, Maria A.
Rettenbacher, Hansjoerg Schweigkofler, Josef Schwitzer and W. Wolfgang
Fleischhacker
European
Psychiatry. Volume 20, Issues 5-6, August 2005, Pages 386-394
Alex Hofer, Susanne
Baumgartner, Thomas Bodner, Monika Edlinger, Martina Hummer, Georg Kemmler,
Maria A. Rettenbacher and W. Wolfgang Fleischhacker
European
Psychiatry. Volume 20, Issues 5-6, August 2005, Pages 395-402
Effectiveness of
clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in
reducing hostile and aggressive behavior in outpatients treated for
schizophrenia: a prospective naturalistic study (IC-SOHO)
Istvan Bitter, Pal
Czobor, Martin Dossenbach and Jan Volavka
European
Psychiatry. Volume 20, Issues 5-6, August 2005, Pages 403-408
Randomized
controlled augmentation trials in clozapine-resistant schizophrenic patients: a
critical review
Vassilis P.
Kontaxakis, Panayotis P. Ferentinos, Beata J. Havaki-Kontaxaki and Dimitris K.
Roukas
European
Psychiatry. Volume 20, Issues 5-6, August 2005, Pages 409-415
Filip Van Den Eede,
Jan Van Hecke, Arjen Van Dalfsen, Bart Van den Bossche, Paul Cosyns and Bernard
G.C. Sabbe
European
Psychiatry. Volume 20, Issues 5-6, August 2005, Pages 422-429
Cortisol/Dehydroepiandrosterone Ratio and Responses to
Antipsychotic Treatment in Schizophrenia
Michael Ritsner, Anatoly Gibel,
Rachel Maayan, Yael Ratner, Edward Ram, Hassan Biadsy, Ilan Modai and Abraham
Weizman
Neuropsychopharmacology (2005) 30, 1913-1922
Increased Pituitary Volume in Antipsychotic-Free and
Antipsychotic-Treated Patients of the
Carmine M Pariante, Paola Dazzan,
Andrea Danese, Kevin D Morgan, Flora Brudaglio, Craig Morgan, Paul Fearon, Ken
Orr, Gerard Hutchinson, Christos Pantelis, Dennis Velakoulis, Peter B Jones,
Julian Leff and Robin M Murray
Neuropsychopharmacology (2005) 30, 1923-1931
Jeffrey
A. Lieberman, T. Scott Stroup, Joseph P. McEvoy, Marvin S. Swartz, Robert A.
Rosenheck, Diana O. Perkins, Richard S.E. Keefe, Sonia M. Davis, Clarence E.
Davis, Barry D. Lebowitz, Joanne Severe, John K. Hsiao, for the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
NEJM. September 19, 2005 (early publication)
Non-uniform blockade of intrastriatal D2/D3
receptors by risperidone and amisulpride
James M. Stone,
Rodrigo A. Bressan, Kjell Erlandsson, Peter J. Ell and
Lyn S. Pilowsky
Psychopharmacology 2005; Volume 180, Number
4: 664 - 669
Faith M. Hanlon,
Michael P. Weisend, Ronald A. Yeo, Mingxiong Huang, Roland R. Lee, Robert J.
Thoma, Sandra N. Moses, Kim M. Paulson, Gregory A. Miller and Jose M. Cañive
Behavioral
Neuroscience. Volume 119, Issue 4, August 2005, Pages 863-875
A prospective study of serum ghrelin levels in patients treated with
clozapine
F. M. Theisen,
S. Gebhardt, T. Brömel, B. Otto, W. Heldwein,
M. Heinzel-Gutenbrunner, J.-C. Krieg, H. Remschmidt,
M. Tschöp and J. Hebebrand
Journal of Neural Transmission 2005; Volume 112,
Number 10: 1411 - 1416
Matthew R. Broome,
James B. Woolley, Paul Tabraham, Louise C. Johns, Elvira Bramon, Graham K.
Murray, Carmine Pariante, Philip K. McGuire and Robin M. Murray
Schizophrenia Research.
Volume 79, Issue 1, 1 November 2005, Pages 23-34
From dopamine to
salience to psychosis—linking biology, pharmacology and phenomenology of
psychosis
Shitij Kapur,
Romina Mizrahi and Ming Li
Schizophrenia Research. Volume 79, Issue 1, 1 November
2005, Pages 59-68
Hélène Verdoux,
Marie Tournier and Audrey Cougnard
Schizophrenia Research. Volume 79, Issue 1, 1 November
2005, Pages 69-75
The relationship
between duration of untreated psychosis and outcome: An eight-year prospective
study
Meredith G. Harris,
Lisa P. Henry, Susy M. Harrigan, Rosemary Purcell, Orli S. Schwartz, Simone E.
Farrelly, Amy L. Prosser, Henry J. Jackson and Patrick D. McGorry
Schizophrenia Research. Volume 79, Issue 1, 1 November
2005, Pages 85-93
Integrated
treatment ameliorates negative symptoms in first episode psychosis—results from
the Danish OPUS trial
A. Thorup, L.
Petersen, P. Jeppesen, J. Øhlenschlæger, T. Christensen, G. Krarup, P.
Jørgensen and M. Nordentoft
Schizophrenia Research. Volume 79, Issue 1, 1 November
2005, Pages 95-105
Determinants of antipsychotic polypharmacy in psychiatric inpatients: a
prospective study
Biancosino, Bruno; Barbui, Corrado; Marmai,
Luciana; Dona, Silna; Grassi, Luigi
International Clinical Psychopharmacology.
20(6):305-309, November 2005
Assessing cardiovascular risks of olanzapine treatment: a 6-month study
versus haloperidol in schizophrenia patients
Barak, Yoram; Swartz, Marnina; Plopsky,
Igor
International Clinical Psychopharmacology.
20(6):315-317, November 2005
A double-blind, cross-over comparison of the effects of amantadine or
placebo on visuomotor and cognitive function in medicated schizophrenia
patients
Silver, Henry; Goodman, Craig; Isakov,
Victoria; Knoll, Gabriela; Modai, Ilan
International Clinical Psychopharmacology.
20(6):319-326, November 2005
Treatment with the new antipsychotic sertindole for late-occurring
undesirable movement effects
Perquin, Lowijs N.M.
International
Clinical Psychopharmacology. 20(6):335-338, November 2005
The Relationship
of Structural Alterations to Cognitive Deficits in Schizophrenia: A Voxel-Based
Morphometry Study
Elena Antonova,
Veena Kumari, Robin Morris, Rozmin Halari, A. Anilkumar, Ravi Mehrotra and
Tonmoy Sharma
Biological Psychiatry. Volume 58, Issue 6, 15 September 2005, Pages
457-467